DPP4 and posterior cortical atrophy: Our results provide a strong mechanistic rationale for re-purposing these agents in PCa treatment, building upon epidemiological studies suggesting improved outcomes in diabetic PCa patients taking DPP4 inhibitors (Pan et al., 2021).